Infectious Disease in Vitro Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Product, Test Location, Technology, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Product Segment Analysis: Reagents (Largest & Fastest-Growing Segment)

The reagents segment accounted for a 2026 share of 64.92% of the infectious disease in vitro diagnostics market, supported by its essential role in enabling accurate and reliable detection across a broad range of infectious diseases. Reagents form the core consumable component of diagnostic workflows, interacting with patient specimens to identify pathogens, antibodies, antigens, or other disease-related biomarkers. Their widespread use across laboratory-based and decentralized testing platforms creates recurring demand as healthcare providers continuously perform diagnostic testing for screening, diagnosis, treatment monitoring, and disease surveillance. The need for dependable and sensitive diagnostic results, particularly during outbreaks and in settings with high testing volumes, further reinforces demand for specialized reagent formulations. As infectious disease testing becomes increasingly focused on faster turnaround, improved analytical sensitivity, and broader pathogen detection, reagent development is also evolving toward more efficient and application-specific solutions. Their compatibility with multiple diagnostic technologies and routine replacement requirements provides the segment with a strong underlying demand base, while expanding infectious disease surveillance and the increasing adoption of advanced testing workflows are expected to support its continued growth.

Test Location Segment Analysis: Central Laboratories (Largest Segment) vs Point of Care (Fastest-Growing Segment)

Central laboratories held the largest 2026 share of 50.94% in the infectious disease in vitro diagnostics market, reflecting their established role in processing high volumes of diagnostic tests with standardized workflows, specialized equipment, and trained laboratory personnel. These facilities are particularly important for complex infectious disease testing that requires sophisticated analytical capabilities, quality-controlled environments, and access to a broad range of diagnostic assays. Hospitals, reference laboratories, and other healthcare institutions continue to rely on centralized testing for confirmatory diagnosis, epidemiological surveillance, and the processing of diverse specimen types. Centralized infrastructure also enables efficient utilization of advanced diagnostic systems and supports consistent testing practices across large patient populations. However, the point of care segment is expected to register the fastest growth as healthcare systems increasingly prioritize rapid diagnosis and treatment decisions closer to the patient. Point-of-care testing can reduce dependence on centralized laboratory workflows and provide results within shorter timeframes, which is particularly valuable for infectious diseases where timely clinical intervention can influence patient management and transmission control. Growing demand for decentralized diagnostics across emergency care, outpatient settings, clinics, and resource-constrained environments is therefore strengthening the adoption of point-of-care testing.

Technology Segment Analysis: Immunoassay (Largest Segment) vs Molecular Diagnostics (Fastest-Growing Segment)

Immunoassay accounted for a 2026 share of 38.59% of the infectious disease in vitro diagnostics market, supported by its broad application in detecting infectious disease markers such as antigens and antibodies. The technology benefits from established laboratory workflows, extensive clinical familiarity, and applicability across a wide range of infectious disease testing requirements. Immunoassays can support high-throughput screening and routine diagnostic applications, making them valuable in hospitals, laboratories, and other healthcare settings where large volumes of samples must be processed efficiently. Their established infrastructure and versatility across different testing formats continue to sustain demand, particularly for routine screening and serological assessment. At the same time, molecular diagnostics is expected to be the fastest-growing technology segment as infectious disease testing increasingly emphasizes direct pathogen detection, high analytical sensitivity, and rapid identification of infectious agents. Molecular approaches can detect pathogen-specific genetic material and are particularly relevant when early-stage diagnosis or differentiation between closely related pathogens is important. The growing need for rapid outbreak investigation, precise pathogen identification, and improved diagnostic accuracy is encouraging healthcare providers to adopt molecular-based testing. Continued technological advancements that simplify molecular workflows and make them more suitable for decentralized and routine clinical environments are further supporting the segment's expansion.